Print Page | Close Window

Investor Overview

Corporate Profile
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in refractory indolent Non-Hodgkin’s Lymphoma (iNHL) and is currently being evaluated in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$2.38
Change (%) Stock is Up 0.06 (2.59%)
Volume168,058
Data as of 06/26/17 11:22 a.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
06/24/17Verastem Reports Phase 2 Long-Term Follow-Up Data for Duvelisib in Patients with Double-Refractory Follicular Lymphoma and Small Lymphocytic Lymphoma at the 22nd Congress of the European Hematology Association
43% ORR per IRC in Patients with Double-Refractory Follicular Lymphoma 68% ORR per IRC in Patients with Double-Refractory Small Lymphocytic Lymphoma Duvelisib Remains Well Tolerated in Long-Term Follow Up BOSTON--(BUSINESS WIRE)--Jun. 24, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the presentation of long-term ... 
Printer Friendly Version
06/07/17Verastem to Present Long-Term Follow-Up Data from the DYNAMO™ Study at the 14th International Conference on Malignant Lymphoma
Duvelisib Monotherapy Treatment Demonstrates 47% ORR in Patients with Double-Refractory Indolent Non-Hodgkin Lymphoma 88% of Patients had a Reduction in the Size of Target Lymph Nodes Duvelisib Remains Well-Tolerated in Long-Term Follow Up BOSTON--(BUSINESS WIRE)--Jun. 7, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announc... 
Printer Friendly Version
05/31/17Verastem to Present at the Jefferies 2017 Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--May 31, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that the company will present at the Jefferies 2017 Global Healthcare Conference on Friday, June 9 at 11:00 a.m. ET at the Grand Hyatt in New York City. A live audio webcast of the presentation will be available on the company’s website at www.vera... 
Printer Friendly Version
05/18/17Verastem Announces Duvelisib Data Presentations at the 22nd Congress of the European Hematology Association
Abstract Highlighting Long-Term Follow Up Data from the DYNAMO® Study of Duvelisib in Patients with Double-Refractory Follicular Lymphoma Selected for Oral Presentation BOSTON--(BUSINESS WIRE)--May 18, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced an abstract featuring long-term follow up data from the DYNAMO® study evaluating duv... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.